Record drug shortages (≥216 active in the US in 2025) expose limited end-to-end visibility, motivating AI-driven early risk detection and coordinated mitigation across fragmented networks.

Seventy-five executives across manufacturers and agencies backed a unified “system of work” to reduce multi-tool fragmentation across core commercial functions, reflecting a shift from tool ...

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes. For decades, pharmaceutical companies have ...

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook. Welcome to Pharma Pulse, ...

BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years. In the final part of Pharmaceutical Commerce’s conversation with Will ...

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence. In the final part of ...

The pharmaceutical supply chain is rapidly entering its “AI-first” phase. Control towers predict delays, reroute shipments, ...

Acting commissioner Kyle Diamantas assumes interim control, prolonging uncertainty until a Senate-confirmed commissioner is installed and governance stabilizes. Elevated leadership churn and perceived ...

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle. In the second part of Pharmaceutical Commerce’s conversation with Tommy Bramley, ...